Cognition Evolution and MRI Markers in PPMS Patients on 2 Years

NAActive, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Multiple Sclerosis, Primary Progressive
Interventions
OTHER

Clinical assessment

Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.

OTHER

Ecological evaluation

Virtual reality task and Actual reality

OTHER

Neuropsychological evaluation

cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function

OTHER

Psychological evaluation

questionnaires for depression, anxiety and fatigue

DEVICE

MRI Evaluation

morphological MRI and resting state functional MRI (fMRI)

Trial Locations (3)

Unknown

CHU de Bordeaux, Bordeaux

CHU de Limoges, Limoges

CHU de Poitiers, Poitiers

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

University Hospital, Bordeaux

OTHER

NCT03455582 - Cognition Evolution and MRI Markers in PPMS Patients on 2 Years | Biotech Hunter | Biotech Hunter